Tenalisib not checked
Rhizen Pharmaceuticals SA · RP6530
FollowEvery change as it happens, and a Monday email
Trials
1 active
7 in total
What this is
- How it works
- Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
- Tested for
- Triple Negative Breast Cancer (TNBC)
- Main trialPhase 2
- “This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.”In the company’s words, NCT06189209 on ClinicalTrials.gov
- Other names
- RP6530
Other drugs for Triple Negative Breast Cancer (TNBC)
- PembrolizumabMerck & Co. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- ESG401Qilu Pharmaceutical · Phase 3
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | |
| Phase 2Completed | 16 Jun 2020 | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | |
| Phase 2Completed | 2 Oct 2020 | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | |
| Phase 2Completed | 31 Mar 2023 | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Withdrawn | Dec 2026 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | |
| Phase 1/2Completed | 14 May 2021 | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | |
| Phase 1/2Completed | 25 Mar 2023 | Compassionate Use Study of Tenalisib (RP6530) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026